SynAct Pharma AB (publ) (“SynAct”) today announced the appointment of Kirsten Harting, MD, as Chief Medical Officer (CMO), effective 15 February 2024. She will lead all clinical development and medical affairs and report to the CEO. Harting brings more than 30 years’ experience to the SynAct team and the company’s push to advance the lead drug candidate resomelagon and its TXP peptide agonists.
Harting joins SynAct following more than three decades within big pharma and biotech as a chief medical officer. She has in-depth knowledge about development with comprehensive early and late clinical phase experience, including the approval of new medicines, combined with business insights. Harting is currently CMO at both Alzinova and Tetra Pharm Technologies and is Medical & Compliance Manager at Sandoz.
“We are happy that Kirsten is joining the SynAct team. Her extensive medical experience and understanding of the biotech space makes Kirsten a fantastic addition to SynAct as we continue to develop resomelagon and our TXP portfolio,” said SynAct’s CEO Torbjørn Bjerke. “We are confident in resomelagon’s potential in treating inflammation and in our TXP peptides platform. Kirsten will play a critical role in helping drive our pipeline forward.”
“I am pleased to join SynAct and get the opportunity to work with the team,” said Harting. “My strength is in clinical development and safety and, I have worked with many indications and compounds, including rheumatoid arthritis and other immunological disorders. Supporting SynAct with its work with resomelagon and its TXP peptide agonists is a perfect fit for me.”
Kirsten Harting earned her MD from the University of Copenhagen and her Executive MBA from the Copenhagen Business School.